Company Overview - Insmed Incorporated is a global biopharmaceutical company focused on delivering first- and best-in-class therapies for patients with serious diseases [2][3] - The company is advancing a diverse portfolio of approved and investigational medicines, particularly in pulmonary and inflammatory conditions, with two approved therapies for chronic lung diseases [2] - Insmed's early-stage programs include various technologies such as gene therapy, AI-driven protein engineering, and synthetic rescue [2] Recent Announcements - Insmed announced management will present at investor conferences, including the Wells Fargo 2025 Healthcare Conference on September 5, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025 [1][4] - The presentations will be webcast live and archived for 30 days on the company's website [1] Company Recognition - Insmed is recognized as one of the best employers in the biopharmaceutical industry, having been named the No. 1 Science Top Employer for four consecutive years [3]